Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
REZPEG's unique mechanism expands regulatory T cells, aiming for durable immune balance rather than rapid symptom suppression, like current IL4/13 inhibitors. While REZPEG's induction data was only moderate versus competitors, its maintenance data confirms the intended, differentiated mechanism of action. NKTR's approach targets long-term disease control in autoimmune conditions, positioning REZPEG as a potential best-in-class therapy. Marcin Roj/iStock via Getty Images Nektar Therapeutics ( NKTR ) is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies for autoimmune and chronic inflammatory diseases, founded in 1990. The company utilizes proprietary technology platforms, including PEGylation, to create drug candidates that modulate This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of NKTR either through stock ownership, options, or other derivatives. I wrote this article myself, an
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple SclerosisPR Newswire
- Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesPR Newswire
- Nektar Therapeutics Announces Pricing of Upsized $400 Million Public OfferingPR Newswire
- Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means [Seeking Alpha]Seeking Alpha
- Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript [Seeking Alpha]Seeking Alpha
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 2/18/26 - Form 144
- 2/18/26 - Form 144
- 2/13/26 - Form SCHEDULE
- NKTR's page on the SEC website